NuVasive - NUVA Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.

9 analysts have issued twelve-month price objectives for NuVasive's shares. Their NUVA share price forecasts range from $44.00 to $63.00. On average, they expect the company's stock price to reach $51.62 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 at the beginning of the year. Since then, NUVA shares have decreased by 23.8% and is now trading at $39.97.
View the best growth stocks for 2022 here.

NuVasive saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,970,000 shares, a decrease of 28.9% from the October 31st total of 2,770,000 shares. Based on an average daily volume of 700,200 shares, the short-interest ratio is presently 2.8 days. Approximately 3.8% of the shares of the company are short sold.
View NuVasive's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Wednesday, November, 9th. The medical device company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $0.01. The medical device company earned $295.30 million during the quarter, compared to analyst estimates of $298.76 million. NuVasive had a positive trailing twelve-month return on equity of 12.49% and a negative net margin of 1.70%. The firm's revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.32 earnings per share.

NuVasive declared that its Board of Directors has authorized a stock repurchase program on Tuesday, November 9th 2021, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 3.5% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

NuVasive updated its FY22 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $2.00-2.10 for the period, compared to the consensus estimate of $2.24. The company issued revenue guidance of ~$1.2-1.213 billion, compared to the consensus revenue estimate of $1.22 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.38%), Thrivent Financial for Lutherans (4.93%), Macquarie Group Ltd. (4.47%), Dimensional Fund Advisors LP (2.58%), Channing Capital Management LLC (2.40%) and Stephens Investment Management Group LLC (1.53%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends.

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $39.97.

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.08 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

The company employs 2,900 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.